0001193125-12-352347.txt : 20120813 0001193125-12-352347.hdr.sgml : 20120813 20120813160205 ACCESSION NUMBER: 0001193125-12-352347 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120813 DATE AS OF CHANGE: 20120813 EFFECTIVENESS DATE: 20120813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VHCP Management, LLC CENTRAL INDEX KEY: 0001479355 IRS NUMBER: 263477966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-14329 FILM NUMBER: 121027685 BUSINESS ADDRESS: STREET 1: 3340 HILLVIEW AVENUE CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 6504753734 MAIL ADDRESS: STREET 1: 3340 HILLVIEW AVENUE CITY: PALO ALTO STATE: CA ZIP: 94304 13F-HR 1 d393337d13fhr.txt FORM 13F-HR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ----------------- FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: June 30, 2012 Check here if Amendment [ ]; Amendment Number: __________ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holding entries. Institutional Investment Manager Filing this Report: Name: VHCP Management, LLC Address: 3340 Hillview Avenue Palo Alto, California 94304 Form 13F File Number: 28- __________ The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: David Stepp Title: General Counsel, VR Management, LLC Phone: (650) 561-9580 Signature, Place, and Date of Signing: /s/ David L. Stepp Palo Alto, California August 13, 2012 -------------------- [Signature] Report Type (Check only one.): [X]13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report) [ ]13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ]13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) FORM 13F SUMMARY PAGE Report Summary:
- Number of Other Included Managers: 0 Form 13F Information Table Entry Total: Seventeen (17) Form 13F Information Table Value Total: $148,057,000 List of Other Included Managers: None
FORM 13F INFORMATION TABLE
Voting Authority TITLE OF VALUE SHARES / SH / PUT / INVESTMENT OTHER --------------------- NAME OF ISSUER CLASS CUSIP (X$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE -------------- -------- ----------- -------- --------- ---- ----- ---------- -------- --------- ------ ---- ACADIA Pharmaceuticals, Inc. COM 004225 10 8 5,897 3,350,785 SH N/A Sole N/A 3,350,785 N/A N/A Alexza Pharmaceuticals, Inc. COM 015384 10 0 2,120 499,999 SH N/A Sole N/A 499,999 N/A N/A Anacor Pharmaceuticals, Inc. COM 032420 10 1 12,980 2,000,000 SH N/A Sole N/A 2,000,000 N/A N/A Anthera Pharmaceuticals, Inc. COM 03674U 10 2 431 637,623 SH N/A Sole N/A 637,623 N/A N/A Array BioPharma Inc. COM 04269X 10 5 1,229 354,100 SH N/A Sole N/A 354,100 N/A N/A Biodel, Inc. COM 09064M 10 5 3,287 1,274,000 SH N/A Sole N/A 1,274,000 N/A N/A Chelsea Therapeutics International, Inc. COM 163428 10 5 5,100 3,446,170 SH N/A Sole N/A 3,446,170 N/A N/A GTx, Inc. COM 40052B 10 8 7,487 2,126,899 SH N/A Sole N/A 2,126,899 N/A N/A Ironwood Pharmaceuticals, Inc. COM 46333X 10 8 33,072 2,400,000 SH N/A Sole N/A 2,400,000 N/A N/A Medivation, Inc. COM 58501N 10 1 11,580 126,699 SH N/A Sole N/A 126,699 N/A N/A Neurocrine Biosciences, Inc. COM 64125C 10 9 21,189 2,683,871 SH N/A Sole N/A 2,683,871 N/A N/A NPS Pharmaceuticals, Inc. COM 62936P 10 3 15,717 1,825,400 SH N/A Sole N/A 1,825,400 N/A N/A Orexigen Therapeutics, Inc. COM 686164 10 4 1,304 235,300 SH N/A Sole N/A 235,300 N/A N/A Spectrum Pharmaceuticals, Inc. COM 84763A 10 8 5,446 350,000 SH N/A Sole N/A 350,000 N/A N/A Tesaro, Inc. COM 881569 10 7 9,189 656,812 SH N/A Sole N/A 656,812 N/A N/A Xenoport, Inc. COM 98411C 10 0 167 27,700 SH N/A Sole N/A 27,700 N/A N/A YM BioSciences, Inc. COM 984238 10 5 11,862 5,961,000 SH N/A Sole N/A 5,961,000 N/A N/A